Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia;Ajustes en la dosis de bivalirudina en función renal disminuida con o sin hemodiálisis para el manejo de trombocitopenia inducida por heparina

Annals of Pharmacotherapy

Volumn 45, Issue 10, 2011, Pages 1185-1192

  Tsu, Laura V ^a   Dager, William E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bivalirudin; Direct thrombin inhibitors; Hemodialysis; Heparin induced thrombocytopenia; Renal failure

Indexed keywords

HIRULOG; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; DIAFILTRATION; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TERTIARY HEALTH CARE; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; CREATININE; DRUG MONITORING; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 80053972454     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q177     Document Type: Article

References (23)

1. Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009;135: 1651-64.DOI 10.1378/chest.08-2830.
2. Warkentin TE, Greinacher A, Koster A, Lincoff AM; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidencebased clinical practice guidelines. 8th ed. Chest 2008;133:340S-80S. DOI 10.1378/chest.126.3_suppl.311S.
3. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: a review of treatment options and special considerations. Pharmacotherapy 2007;27: 564-87.
4. Seybert AL, Coons JC, Zerumsky K. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy 2006;26: 229-41.DOI 10.1592/phco.26.2.229.
5. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006;26: 452-60.DOI 10.1592/phco.26.4.452.
6. Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2008;28: 1115-24.DOI 10.1592/phco.28.9.1115.
7. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006;26: 461-8.DOI 10.1592/phco.26.4.461.
8. Package information. Angiomax (bivalirudin). Bedford, OH: BenVenue Laboratories, December 2005.
9. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004;121: 593-9.DOI 10.1309/D79K-4YG7-8NTN-YY38.
10. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002;71: 433-9. DOI 10.1067/mcp.2002.124522.
11. Dowling TC. Clinical assessment of kidney function. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York, NY: McGraw-Hill, 2011:729.
12. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3: 692-4. DOI 10.1111/j.1538-7836.2005.01204.x
13. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121: 535-55. DOI 10.1046/j.1365-2141.2003.04334.x
14. Janatpour KA, Gosselin RC, Dager WE, et al. Usefulness of optical density values from heparin-platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia. Am J Clin Pathol 2007;127: 429-33. DOI 10.1309/815R-8388-R776-48Q0
15. Skrupky LP, Smith JR, Deal EN, et al. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy 2010;30: 1229-38. DOI 10.1592/phco.30.12.1229.
16. Dager WE. Considerations for drug dosing post coronary artery bypass graft surgery. Ann Pharmacother 2008;42:421-4. DOI 10.1345/aph.1L009
17. Delhaye C, Maluenda G, Wakabayashi K, et al. Safety and in-hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention. Am J Cardiol 2010;105: 297-301.DOI 10.1016/j.amjcard.2009.09.030.
18. Coritsidis GN. Sustained low-efficiency daily dialysis as renal replacement therapy for the critically ill. ICU Director 2010;1(4): 210-3.DOI 10.1177/1944451610378744.
19. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003;15: 611-6.
20. Lubenow N, Eichler P, Greinacher A. Results of a large drug monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia (abstract). Blood 2002;100:502a.
21. Lubenow N, Eichler P, Lietz T, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004;104:3072-7. DOI 10.1182/blood-2004-02-0621.
22. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103: 1838-43. DOI 10.1016/S1062-1458(01)00367-1
23. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-56. DOI 10.1016/S1062-1458(01)00367-1